Skip to content

Abstract 11768: Association Between Clinical Events and Subsequent Events Among Anticoagulant Treated Patients with Atrial Fibrillation: Real World Data Analyses in US and UK

Nov 2026 · Circulation · Vol 154 · 0 citations

TL;DR

In contemporary OAC-treated AF populations, the occurrence of thrombotic or bleeding events was associated with a marked increase in the risk of recurrent events and all-cause mortality.

Abstract

Background: Oral anticoagulants (OACs) reduce the risk of thromboembolic events in atrial fibrillation (AF) patients; but thrombotic and bleeding events still occur. More evidence is needed on how prior events affect future event risk and mortality. Research Question: To quantify associations between the first occurrence of clinical events of interest, “prior” clinical events, defined as ischemic stroke/systemic embolism (IS/SE), major bleed (MB), intracranial hemorrhage (ICH), myocardial infarction (MI) and the risk of subsequent clinical events (IS/SE, MB, ICH, MI, cardiovascular (CV) and all-cause mortality) among OAC-treated AF patients. Methods: Adults with newly diagnosed AF initiating an OAC within 90 days of AF diagnosis were included from the UK Clinical Practice Research Datalink linked to Hospital Episode Statistics and US Medicare claims (2012-2021), separately. Patients were tracked from their first OAC prescription after AF diagnosis until death or end of data. The first clinical event of interest was required to occur on treatment. Subsequent non-fatal IS/SE, MB, ICH and MI were analyzed using Andersen-Gill gap-time models; CV and all-cause mortality were analyzed using Cox regression. Results: The study included 70,887 UK and 314,818 US patients (mean age 77 years; 53% male). In the UK cohort, 70.1% initiated direct OACs and 29.9% initiated vitamin K antagonists; corresponding proportions in the US cohort were 74.3% and 25.7%. Prior events substantially increased the risk of recurrence of the same event: in the UK, each prior IS/SE increased the risk of subsequent IS/SE by 153% (HR 2.5, 95% CI 2.3-2.8); each prior MB increased risk of subsequent MB by 89% (HR 1.9, 95% CI 1.8-1.9); and each prior MI increased risk of subsequent MI by 260% (HR 3.6, 95% CI 3.1-4.2); corresponding estimates from the US cohort were 150%, 93% and 144% (Table 1). Additionally, prior MB events were associated with 33-41% increased risk of subsequent IS/SE in both UK and US cohorts. Finally, prior clinical events were associated with substantially higher all-cause mortality, ranging from a 51% to 161% increase depending on event type and cohort (Table 1). Conclusions: In contemporary OAC-treated AF populations, the occurrence of thrombotic or bleeding events was associated with a marked increase in the risk of recurrent events and all-cause mortality. These findings underscore the importance of continuous risk reassessment and highlight the substantial risk of clinical events that persist despite current anticoagulant therapy.

View source

Similar papers

Nov 2026

Abstract 14409: Residual Risk of Ischemic Stroke Despite Anticoagulation in Patients Hospitalized with Atrial Fibrillation: Insights from the Get With The Guidelines-Atrial Fibrillation Program

Background: Oral anticoagulation (OAC) substantially reduces stroke risk in atrial fibrillation (AF), yet residual risk persists even among treated patients. Contemporary real-world data on this residual risk, its determinants, and longitudinal adherence to OAC are limited. Methods: We analyzed patients ≥65 ye...

B. Deb, L. Kaltenbach, K. Chiswell et al. · 0 citations
Nov 2026

Abstract 13527: Real World Evidence of the Consequences of Bleeding Events on Anticoagulant Use in Patients with Atrial Fibrillation in the United States

Background: Oral anticoagulation (OAC) reduces stroke risk in atrial fibrillation (AF), but major bleeding (MB) remains a concern. Current evidence on post-bleeding treatment patterns is limited. Question: How does bleeding influence OAC treatment patterns in the real-world? Methods: This retrospective s...

Mahmoud A. Hashim, E. O'Brien, A. Kang et al. · 0 citations
Nov 2026

Abstract 18923: Prognostic Significance of Anticoagulation in Kidney Failure-Triggered Acute Illness Associated Atrial Fibrillation (AIAAF): The SAFE AF Study (Acronyms: SAFE-AF: Stroke Prevention, Anticoagulation, Fibrillation Control, Evaluation for Reversible Causes in Atrial Fibrillation)

Background: Current AHA and ESC guidelines acknowledge that standard risk scores are poorly calibrated for acute illness, leaving a gap in evidence-based management. Consequently, AIAAF in acute kidney failure often triggers therapeutic nihilism due to concerns of hemostatic fragility. Research Hypothesis: We...

M. Elashry, H. C. Kalangi, Nan Zhang et al. · 0 citations
Open access Oct 2026

Clinical outcomes following atrial fibrillation diagnosis in routine practice: a nationwide cohort study in Sweden

Patients diagnosed with atrial fibrillation (AF) are at risk of clinically meaningful ischaemic and haemorrhagic events, and death. Contemporary data are essential to define residual risk in the real-world setting and to help identify the current unmet need. To describe the occurrence and cumulative incide...

K. Smith, P. Sandin, A. Beaudet et al. · 0 citations
Nov 2026

Abstract 13600: Evaluation of the Risk of All-Cause Mortality With and Without Antithrombotic Therapy in Patients with Newly Diagnosed Atrial Fibrillation and Low-to-Moderate Stroke Risk

Background: Evidence regarding the impact of antithrombotic therapy on mortality in atrial fibrillation (AF) patients with low-to-moderate stroke risk remains uncertain. We evaluated the risk of all-cause mortality in low-to-moderate stroke risk AF patient categories and examine the association of event rates with a...

R. Cappato · 0 citations
Nov 2026

Abstract 5578: Adverse Clinical Events in Secondary Stroke Prevention: A Nationwide Cohort Study in Sweden

Introduction: Despite improvements in the management of ischemic stroke (IS), survivors continue to face high risk of recurrent events, including IS, major adverse vascular events (MAVE), and bleeding. Long-term real-world evidence is needed to characterize the burden of recurrent events under current secondary stro...

Meghan Thompson, J. Banefelt, A. Beaudet et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.